EBS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EBS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Emergent BioSolutions's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $18.916. Emergent BioSolutions's 10-Year median PS Ratio is 3.4368. Therefore, the Median PS Value for today is $65.01.
As of today (2025-04-11), Emergent BioSolutions's share price is $4.39. Emergent BioSolutions's Median PS Value is $65.01. Therefore, Emergent BioSolutions's Price to Median PS Value for today is 0.07.
The historical rank and industry rank for Emergent BioSolutions's Median PS Value or its related term are showing as below:
During the past 13 years, the highest Price to Median PS Value of Emergent BioSolutions was 1.69. The lowest was 0.03. And the median was 0.89.
The historical data trend for Emergent BioSolutions's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emergent BioSolutions Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Median PS Value | Get a 7-Day Free Trial |
![]() |
![]() |
94.79 | 106.79 | 75.52 | 69.84 | 65.01 |
Emergent BioSolutions Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Median PS Value | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
69.84 | 77.90 | 71.58 | 71.71 | 65.01 |
For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Emergent BioSolutions's Price-to-Median-PS-Value falls into.
Emergent BioSolutions's Median PS Value for today is calculated as
Median PS Value | = | Revenue per Share (TTM) | * | 10-Year Median PS Ratio |
= | 18.916 | * | 3.4368 | |
= | 65.01 |
10-Year Median PS Ratio is 3.4368.
Emergent BioSolutions's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $18.916.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emergent BioSolutions (NYSE:EBS) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Emergent BioSolutions's Price to Median PS Value for today is calculated as
Price to Median PS Value | = | Share Price | / | Median PS Value |
= | 4.39 | / | 65.01 | |
= | 0.07 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Emergent BioSolutions's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Neal Franklin Fowler | director | C/O EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879 |
Kathryn C Zoon | director | 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879 |
Donald W Degolyer | director | 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879 |
Marvin L White | director | 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850 |
William Hartzel | officer: SVP, Bioservices | 400 PROFESSIONAL DRIVE, STE. 400, GAITHERSBURG MD 20879 |
Miller H Haywood Iii | officer: Interim CEO | EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879 |
Paul Anthony Williams | officer: SVP, Products Business | 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879 |
Ronald Richard | director | 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850 |
Sujata Tyagi Dayal | director | C/O BIOMET, INC., P.O. BOX 587, WARSAW IN 46581-0587 |
Keith Katkin | director | C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617 |
Glessner Coleen | officer: EVP, Quality & Ethics, and CPL | 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879 |
Jennifer Lynne Fox | officer: EVP, Ext Aff, GC, Corp Sec | 400 PROFESSIONAL DRIVE, GAITHERSBURG MD 20879 |
Richard S Lindahl | officer: EVP, Chief Financial Officer | NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191 |
Sue Bailey | director | 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20850 |
Adam Havey | officer: EVP, BioDefense Division | 2273 RESEARCH BLVD SUITE 400, ROCKVILLE MD 20853 |
From GuruFocus
By GuruFocus News • 01-22-2025
By Marketwired • 12-16-2024
By Marketwired • 03-10-2025
By Marketwired • 01-08-2025
By Marketwired • 01-14-2025
By Marketwired • 03-18-2025
By Marketwired • 03-12-2025
By GuruFocus News • 11-14-2024
By GuruFocus News • 11-12-2024
By GuruFocus News • 03-04-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.